Th1 - CD11c B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis

Overview

Journal Ann Neurol

Specialty Neurology

Date 2021 Aug 23

PMID 34424567

Citations 3

Authors

Kimitoshi Kimura

Youwei Lin

Hiromi Yamaguchi

Wakiro Sato

Daiki Takewaki

Misako Minote

Yoshimitsu Doi

Tomoko Okamoto

Ryosuke Takahashi

Takayuki Kondo

Takashi Yamamura

Affiliations

Soon will be listed here.

Abstract

Objective: Although plasmapheresis is a treatment option for patients with autoimmune neurological diseases, treatment response varies greatly among patients. The main objective of this study was to find out if biological/immune traits correlate with a beneficial response.

Methods: We thoroughly analyzed immune phenotypes in paired blood samples from a cohort of 31 patients with multiple sclerosis before and after plasmapheresis, in parallel with clinical evaluation of treatment response.

Results: The frequency of IFN-γ Th1 cells was persistently higher in those who obtained benefit from plasmapheresis (responders) than nonresponders. The Th1 cell frequency before plasmapheresis provided a high predictive value for beneficial response, achieving area under the curve (AUC) of 0.902. Plasmapheresis treatment decreased inflammation-related gene expressions in Th1 cells. Meanwhile, IFNG expression in Th1 cells positively correlated with the frequency of CD11c B cells, of which a pathogenic role has been suggested in several autoimmune diseases. In line with this, in vitro experiments showed that CD11c B cells would increase in response to exogenous IFN-γ compared to IL-4, and secrete high amounts of IgG. B cell receptor analysis indicated that clonal expansion of CD11c B cells takes place in patients with multiple sclerosis. Interestingly, CD11c B cells, which showed unique gene expression profile, decreased after plasmapheresis treatment along with all the immunoglobulin subsets in the circulation.

Interpretation: Taken together, we postulate that Th1 cell - CD11c B cell axis is involved in treatment response to plasmapheresis, giving us clues to better understanding of complicated pathogenesis of autoimmune diseases, and getting closer to a personalized therapy. ANN NEUROL 2021;90:595-611.

Citing Articles

Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators.

Hecker M, Fitzner B, Ludwig-Portugall I, Bohne F, Heyland E, Klehmet J Front Immunol. 2025; 16:1531447.

PMID: 39949773 PMC: 11821495. DOI: 10.3389/fimmu.2025.1531447.

CD11c B Cell Expansion Is Associated With Severity and Brain Atrophy in Neuromyelitis Optica.

Amano E, Sato W, Kimura Y, Kimura A, Lin Y, Okamoto T Neurol Neuroimmunol Neuroinflamm. 2024; 11(2):e200206.

PMID: 38350043 PMC: 11073873. DOI: 10.1212/NXI.0000000000200206.

Age/autoimmunity-associated B cells in inflammatory arthritis: An emerging therapeutic target.

Li Z, Cai M, Qin Y, Chen Z Front Immunol. 2023; 14:1103307.

PMID: 36817481 PMC: 9933781. DOI: 10.3389/fimmu.2023.1103307.

Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis.

Tomas-Ojer P, Puthenparampil M, Cruciani C, Docampo M, Martin R, Sospedra M Front Neurol. 2022; 13:790884.

PMID: 35185762 PMC: 8852676. DOI: 10.3389/fneur.2022.790884.

References

Lee N, Ha S, Sati P, Absinta M, Luciano N, Lefeuvre J . Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. Brain. 2018; 141(6):1637-1649. PMC: 5972667. DOI: 10.1093/brain/awy082. View

Vos C, Geurts J, Montagne L, van Haastert E, Bo L, van der Valk P . Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis. 2005; 20(3):953-60. DOI: 10.1016/j.nbd.2005.06.012. View

Magliozzi R, Hametner S, Facchiano F, Marastoni D, Rossi S, Castellaro M . Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. Ann Clin Transl Neurol. 2019; 6(11):2150-2163. PMC: 6856609. DOI: 10.1002/acn3.50893. View

Isnardi I, Ng Y, Menard L, Meyers G, Saadoun D, Srdanovic I . Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood. 2010; 115(24):5026-36. PMC: 3373152. DOI: 10.1182/blood-2009-09-243071. View

Claes N, Fraussen J, Vanheusden M, Hellings N, Stinissen P, Van Wijmeersch B . Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients. J Immunol. 2016; 197(12):4576-4583. DOI: 10.4049/jimmunol.1502448. View

Christensen S, Shupe J, Nickerson K, Kashgarian M, Flavell R, Shlomchik M . Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006; 25(3):417-28. DOI: 10.1016/j.immuni.2006.07.013. View

Wilson R, Makuch M, Kienzler A, Varley J, Taylor J, Woodhall M . Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. Brain. 2018; 141(4):1063-1074. PMC: 5889028. DOI: 10.1093/brain/awy010. View

Schimrigk S, Faiss J, Kohler W, Gunther A, Harms L, Kraft A . Escalation Therapy of Steroid Refractory Multiple Sclerosis Relapse with Tryptophan Immunoadsorption - Observational Multicenter Study with 147 Patients. Eur Neurol. 2016; 75(5-6):300-6. DOI: 10.1159/000447059. View

Osman C, Jennings R, El-Ghariani K, Pinto A . Plasma exchange in neurological disease. Pract Neurol. 2019; 20(2):92-99. DOI: 10.1136/practneurol-2019-002336. View

10.

Ryu J, Rafalski V, Meyer-Franke A, Adams R, Poda S, Rios Coronado P . Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol. 2018; 19(11):1212-1223. PMC: 6317891. DOI: 10.1038/s41590-018-0232-x. View

11.

Obeng-Adjei N, Portugal S, Holla P, Li S, Sohn H, Ambegaonkar A . Malaria-induced interferon-γ drives the expansion of Tbethi atypical memory B cells. PLoS Pathog. 2017; 13(9):e1006576. PMC: 5633206. DOI: 10.1371/journal.ppat.1006576. View

12.

Stork L, Ellenberger D, Beissbarth T, Friede T, Lucchinetti C, Bruck W . Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. JAMA Neurol. 2018; 75(4):428-435. PMC: 5885209. DOI: 10.1001/jamaneurol.2017.4842. View

13.

Ryu J, Petersen M, Murray S, Baeten K, Meyer-Franke A, Chan J . Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. 2015; 6:8164. PMC: 4579523. DOI: 10.1038/ncomms9164. View

14.

Koziolek M, Tampe D, Bahr M, Dihazi H, Jung K, Fitzner D . Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation. 2012; 9:80. PMC: 3418188. DOI: 10.1186/1742-2094-9-80. View

15.

Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, Defrance T . TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol. 2007; 178(12):7779-86. DOI: 10.4049/jimmunol.178.12.7779. View

16.

Kitaura K, Yamashita H, Ayabe H, Shini T, Matsutani T, Suzuki R . Different Somatic Hypermutation Levels among Antibody Subclasses Disclosed by a New Next-Generation Sequencing-Based Antibody Repertoire Analysis. Front Immunol. 2017; 8:389. PMC: 5413556. DOI: 10.3389/fimmu.2017.00389. View

17.

Peng S, Szabo S, Glimcher L . T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci U S A. 2002; 99(8):5545-50. PMC: 122806. DOI: 10.1073/pnas.082114899. View

18.

Jangi S, Gandhi R, Cox L, Li N, von Glehn F, Yan R . Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016; 7:12015. PMC: 4931233. DOI: 10.1038/ncomms12015. View

19.

Saadoun D, Terrier B, Bannock J, Vazquez T, Massad C, Kang I . Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation. Arthritis Rheum. 2013; 65(4):1085-96. PMC: 4479193. DOI: 10.1002/art.37828. View

20.

Rubtsova K, Rubtsov A, van Dyk L, Kappler J, Marrack P . T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance. Proc Natl Acad Sci U S A. 2013; 110(34):E3216-24. PMC: 3752276. DOI: 10.1073/pnas.1312348110. View